Consider sending a letter to the editor of your local paper.  Here's some copy to get you started:

The Department of Defense is giving hope to the more than two million men currently suffering with prostate cancer in the United States.  But while the death rate has been reduced by 40 percent in the past few years, prostate cancer remains the second cause of death from cancer in US men.

The Department’s Congressionally Directed Medical Research Program (CDMRP), the second-largest funded prostate cancer research program in the U.S., has been supporting innovative research to end death from prostate cancer and doing it at high efficiency.  Similar programs at the Department have helped develop lifesaving drugs for breast cancer and leukemia.  Now the prostate cancer research project is closing-in on potential new “targeted medicines” that might replace chemotherapy.

However, a nearly eight-year funding plateau has stretched the program to the breaking-point.  The prostate cancer research project’s flat-funding is allowing inflation and increased research costs to slowly erode the program’s impressive and precious research base.

This is a program with an excellent record.  It requires researchers to define milestones and document meeting them for continued funding.  In an economy where poor business decisions have cost taxpayers billions of dollars, the CDMRP is on the cutting-edge of research to bring treatments to the 200,000 fathers and brothers and sons who will be diagnosed with the disease this year. Congress needs to reward efficiency, innovation and accountability with the full funding needed by this highly effective program.